Durvalumab After Chemoradiotherapy for Patients With Unresectable Stage III NSCLC: The PACIFIC-R Study-Reference-Cited by-同舟云学术

Durvalumab After Chemoradiotherapy for Patients With Unresectable Stage III NSCLC: The PACIFIC-R Study

Published:2023-04 Issue:4 Volume:18 Page:e38-e39
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Zhao Binghao,Li Huanzhang,Ma Wenbin

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference5 articles.

1. Treatment characteristics and real-world progression-free survival in patients with unresectable stage III NSCLC who received durvalumab after chemoradiotherapy: findings from the PACIFIC-R study;Girard;J Thorac Oncol,2023

2. Analysis of real-world data to investigate the impact of race and ethnicity on response to programmed cell Death-1 and programmed cell death-ligand 1 inhibitors in advanced non-small cell lung cancers;Ayers;Oncologist,2021

3. Persistent ethnicity-associated disparity in anti-tumor effectiveness of immune checkpoint inhibitors despite equal access;Florez;Cancer Res Commun,2022

4. Durvalumab after sequential chemoradiotherapy in stage III, unresectable NSCLC: the phase 2 PACIFIC-6 trial;Garassino;J Thorac Oncol,2022

5. The impact of radiological assessment schedules on progression-free survival in metastatic breast cancer: a systemic review and meta-analysis;Dabush;Cancer Treat Rev,2021

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Outcomes of Subsequent Chemotherapy after Progression Following Chemoradiation and Consolidative Durvalumab Therapy in Locally Advanced Non-small Cell Lung Cancer: An Exploratory Analysis from the CRIMSON Study (HOPE-005);Clinical Lung Cancer;2024-07

2. Osimertinib Versus Durvalumab Versus Observation After Chemoradiation in Unresectable EGFR-Mutant NSCLC;Journal of Thoracic Oncology;2024-05

3. Radiotherapy combined with EGFR-TKIs for stage III EGFR-Mutated lung cancer: A retrospective cohort study;2024-03-15

4. αPD-1 immunotherapy promotes IL-17A production and promotes the formation of acute radiation-induced lung injury;American Journal of Cancer Research;2024